CD Formulation has been dedicated to the research of long-acting injectable liposomes for numerous years, aiming to enhance drug effectiveness and patient compliance, thereby offering improved treatment options for patients. Our development platform for injectable liposome formulations focuses on various indications including systemic fungal infections, tumors, vaccines, pain relief, etc. We are dedicated to advancing the field of injectable liposomes by harnessing state-of-the-art technologies, including degradable and injectable polymer liposome hydrogels, PEG-modified liposomes, and environmentally responsive liposomes. As a professional pharmaceutical R&D team with an exceptional platform and extensive experience, we consistently strive to offer patients more advanced and effective treatment options. By choosing to collaborate with us, you will benefit from our profound professional background, rich project experience, and efficient cooperation team while jointly advancing the field of liposome formulations.
Liposome formulations present a novel approach to delivering drugs, offering numerous benefits such as the ability to carry high drug loads, excellent compatibility with biological systems, and controlled release of medications. These characteristics make liposome formulations highly promising for injectable applications in drug delivery and have been proven effective in delivering various types of drugs including proteins, peptides, and small molecules, making them applicable in treating a wide range of diseases like cancer, diabetes, and cardiovascular disorders. Additionally, liposome formulations can improve the availability and pharmacokinetic properties of drugs while enhancing their effectiveness and reducing adverse reactions.
The development process for injectable liposome formulations requires careful consideration of factors such as liposome composition, optimizing size parameters, and modifying surface properties that directly impact both efficacy and safety profiles. Therefore, achieving highly efficient injectable liposome formulations necessitates comprehensive studies on preparing liposomes and understanding drug delivery mechanisms while considering the physicochemical properties and biodistribution characteristics specific to each medication. Developing long-acting injectable liposome formulations holds immense significance in improving therapeutic outcomes while minimizing adverse reactions.
Our services cover the entire R&D process of injectable liposome development, including formulation design and screening, in vitro pharmacodynamic evaluation, testing phase and mass production challenges.
In this service, we design the optimal according to the needs of customers through scientific technical means and conduct screening to ensure the quality and effect of the product.
In this stage, we employ advanced experimental techniques to assess the pharmacodynamic impact of the liposome, ensuring its efficacy in practical applications via vitro models such as cell models, animal models,etc.
During the testing phase, we conduct comprehensive evaluations of the product, encompassing safety and efficacy assessments, in order to ensure compliance with national and industry standards.
In the mass production stage, we guarantee product quality and stability through a scientific manufacturing process and rigorous quality control measures to meet customer requirements. We ensure smooth transfer of methods from the laboratory phase to the scale-up phase and control differences between batches.
Fig.1 The workflow of injectable liposome formulation development. (CD Formulation)
Technology Platform | Specific contents |
Formulation Development Technology | To design the optimal according to the needs of customers through scientific technical means and conduct screening to ensure the quality and effect of the product. |
Lysolipid Thermally Sensitive Liposome (LTSL) Technology | The primary application of LTSL is for the targeted release of drugs at elevated temperature sites. It is customary to employ lipids with phase transition temperatures ranging from 40°C to 45°C during the formulation process of these liposomes. |
Non-PEGylated Liposome (NPL) Technology | The NPL represent a distinctive drug delivery system that encompasses the advantages of PEGylated liposomes while mitigating the associated side effects of PEG. |
Analysis Platform | To provide an in-depth characterization and evaluation of the pharmacodynamics and stability of liposomes by meticulously analyzing their pharmacodynamic properties, stability, and potential applications in various therapeutic areas. |
Technology: New Long-lasting Liposome Adenosine Drug Delivery Technology
Journal : Dsteoarthritis and Cartilage
IF : 7.0
Published : 2024
Results : In this study, the author used a novel longlasting formulations technology to deveop a injetable liposomal adenosine in the treatment of OA in a preclinical canine model. It was demonstrated that the liposome contributes to the upregulation of genes related to inflammation expression and contributes to the continuation of the inflammatory environment in osteoarthritis.
Fig.2 Pharmacodynamic evaluation. (Siddhesh R. Angle, et al., 2024)
Our team at CD Formulation comprises a group of devoted researchers who are fully dedicated to addressing any obstacles that may emerge throughout the process of developing injectable liposomes. If you have any interest, please feel free to contact us without delay.
References